Emergent BioSolutions Hits New 52-Week High of $13.41, Up 100.94%

Emergent BioSolutions, Inc. has reached a significant milestone by hitting a new 52-week high of USD 13.41 on October 30, 2025. This achievement marks a remarkable increase in the stock's value, reflecting a year-over-year performance of 100.94%, significantly outpacing the S&P 500's growth of 18.13% during the same period.
As a microcap company in the Pharmaceuticals & Biotechnology sector, Emergent BioSolutions has a market capitalization of USD 412 million. The company has demonstrated a solid return on equity of 26.51%, indicating effective management of shareholder equity. Additionally, the stock's price-to-book ratio stands at 0.77, suggesting that it may be undervalued relative to its assets.

Despite the absence of a dividend yield and a loss-making status reflected in the P/E ratio, the company's debt-to-equity ratio of 0.74 indicates a manageable level of debt. The stock's previous 52-week low was recorded at USD 4.02, highlighting the significant upward trajectory it has experienced over the past year.